We are monitoring the impact of COVID-19 on Europe Melanoma Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 794
Share on
Share on

Europe Melanoma Therapeutics Market Research Report - Segmented By Cancer Stage, Cancer Type, Diagnosis, Treatment and Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic and Rest of Europe) - Industry Analysis, Size, Share, Growth, Trends and Forecast (2019 - 2024)

Pulished: February, 2020
ID: 794
Pages: 145

Europe Melanoma Therapeutics Market Size & Growth (2019 - 2024)

The size of the Melanoma Therapeutics Market in Europe was worth USD 0.72 billion in 2019 and estimated to be growing at a CAGR of 16.20%, to reach USD 1.54 billion by 2024. 

The melanoma market has seen an unparalleled boost in market size, owing to a vigorously developing nature of melanoma treatments over the recent past.

Melanoma denotes to the type of skin cancer which forms from the pigment-consisting cells in the skin. The elevated demand of innovative early stage and advanced melanoma treatments along with a thriving patient base, has generated an imminent need for improved therapies in the melanoma market. Even though, a plethora of treatment choices are accessible today, various immunotherapies and combination therapies are anticipated to arrive in the market.

Rise in Melanoma cases is one of the major driver for the Melanoma Therapeutics market in this region. Other factors such as high acceptance rate of therapeutics among patients, and government policies to provide better care for melanoma also drive the market in this region.

However, high costs incurred due to treatment is one of the major factor hindering the growth of the market in this region.

This research report segmented and sub-segmented into the following categories:

  • By Cancer Stage: Stage 0, Stage I, Stage II, Stage III and Stage IV
  • By Cancer Type: Nodular Melanoma, Acral Lentiginous Melanoma, Superficial Spreading Melanoma, Lentigno Maligna Melanoma, Amelanotic Melanoma and Others
  • By Diagnosis: Ultrasound, Blood Tests, Dermatoscopy, Sentinel Lymph Node Biopsy, X-rays and CT Scan
  • By Treatment: Early Melanoma, Advanced Melanoma-Biological Therapy, Targeted Therapy, Surgery, Chemotherapy, Radiotherapy and Immune Therapy
  • By Country: UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic and Rest of Europe

The Europe Melanoma Therapeutics market is the third largest market with a global share of 24%. UK is the largest market share holder for the Melanoma Therapeutics market in this region, followed by Germany and France.

Promising companies leading the European Melanoma Therapeutics Market profiled in this report are Bristol-Myers Squibb Co., Merck and Co., F. Hoffmann-La Roche, Amgen Inc., Celgene Corp, Daiichi Sankyo, and Pfizer Inc.

1. Introduction                             

              1.1 Market Definition                  

              1.2 Study Deliverables                

              1.3 Base Currency, Base Year and Forecast Periods                       

              1.4 General Study Assumptions              

2. Research Methodology                                       

              2.1 Introduction                           

              2.2 Research Phases                    

                             2.2.1 Secondary Research          

                             2.2.2 Primary Research

                             2.2.3 Econometric Modelling     

                             2.2.4 Expert Validation 

              2.3 Analysis Design                      

              2.4 Study Timeline                       

3. Overview                                   

              3.1 Executive Summary              

              3.2 Key Inferences                       

              3.3 New Developments              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                

              4.1 Market Drivers                       

              4.2 Market Restraints                  

              4.3 Key Challenges                       

              4.4 Current Opportunities in the Market                           

5. Market Segmentation                                          

              5.1 By cancer stage                      

                             5.1.1 Stage 0     

                             5.1.2 Stage I      

                             5.1.3 Stage II     

                             5.1.4 Stage III   

                             5.1.5 Stage IV   

              5.2 By cancer type                        

                             5.2.1 Nodular melanoma           

                             5.2.2 Acral lentiginous melanoma          

                             5.2.3 Superficial spreading melanoma  

                             5.2.4 Lentigno maligna melanoma         

                             5.2.5 Amelanotic melanoma     

                             5.2.6 Others     

              5.3 By Diagnosis                           

                             5.3.1 Ultrasound            

                             5.3.2 Blood Tests           

                             5.3.3 Dermatoscopy      

                             5.3.4 Sentinel lymph node biopsy           

                             5.3.5 X-rays       

                             5.3.6 CT Scan    

              5.4 By Treatment                         

                             5.4.1 Early melanoma   

                             5.4.2 Advanced melanoma        

                                           5.4.2.1 Biological therapy

                                           5.4.2.2 Targeted therapy

                                           5.4.2.3 Surgery

                                           5.4.2.4 Chemotherapy

                                           5.4.2.5 Radiotherapy

                                           5.4.2.6 Immune therapy

6. Geographical Analysis                                         

              6.1 Introduction                           

              6.2 U.K               

              6.3 Spain                          

              6.4 Germany                   

              6.5 Italy                            

              6.6 France                       

7. Pipeline Product Analysis                                    

              7.1 Overview                                 

              7.2 Pipeline Development Landscape                                 

              7.3 Molecular Targets in the Pipeline                                  

              7.4 Clinical Trials                          

                             7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target    

                             7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target             

                             7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.   

8. Strategic Analysis                                   

              8.1 PESTLE analysis                      

                             8.1.1 Political    

                             8.1.2 Economic

                             8.1.3 Social       

                             8.1.4 Technological       

                             8.1.5 Legal         

                             8.1.6 Environmental     

              8.2 Porter’s Five analysis                          

                             8.2.1 Bargaining Power of Suppliers       

                             8.2.2 Bargaining Power of Consumers   

                             8.2.3 Threat of New Entrants    

                             8.2.4 Threat of Substitute Products and Services             

                             8.2.5 Competitive Rivalry within the Industry     

9. Market Leaders' Analysis                                    

              9.1 Bristol-Myers Squibb Co                     

                             9.1.1 Overview 

                             9.1.2 Product Analysis  

                             9.1.3 Strategic Evaluation and Operations          

                             9.1.4 Financial analysis 

                             9.1.5 Legal issues           

                             9.1.6 Recent Developments       

                             9.1.7 SWOT analysis      

                             9.1.8 Analyst View         

              9.2 Merck and Co                         

              9.3 F. Hoffmann-La Roche                        

              9.4 Amgen Inc                

              9.5 Celgene Corp                          

              9.6 Daiichi Sankyo                        

              9.7 Pfizer Inc                   

10. Competitive Landscape                                     

              10.1 Market share analysis                      

              10.2 Merger and Acquisition Analysis                  

              10.3 Agreements, collaborations and Joint Ventures                    

              10.4 New Product Launches                     

11. Expert Opinions                                   

              11.1 Market Outlook                   

              11.2 Investment Opportunities               

Appendix                                       

              a) List of Tables              

              b) List of Figures                           

  • Regional, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Europe Melanoma Therapeutics Market By Region, From 2019-2024(USD Billion)
  2. Europe Melanoma Therapeutics Market By Cancer stage , From 2019-2024(USD Billion)
  3. Europe Stage 0 Market By Region, From 2019-2024(USD Billion)
  4. Europe Stage I Market By Region, From 2019-2024(USD Billion)
  5. Europe Stage II Market By Region, From 2019-2024(USD Billion)
  6. Europe Stage III Market By Region, From 2019-2024(USD Billion)
  7. Europe Stage IV Market By Region, From 2019-2024(USD Billion)
  8. Europe Melanoma Therapeutics Market By Cancer type , From 2019-2024(USD Billion)
  9. Europe Nodular melanoma Market By Region, From 2019-2024(USD Billion)
  10. Europe Acral lentiginous melanoma Market By Region, From 2019-2024(USD Billion)
  11. Europe Superficial spreading melanoma Market By Region, From 2019-2024(USD Billion)
  12. Europe Lentigno maligna melanoma Market By Region, From 2019-2024(USD Billion)
  13. Europe Amelanotic melanoma Market By Region, From 2019-2024(USD Billion)
  14. Europe Other cancers Market By Region, From 2019-2024(USD Billion)
  15. Europe Melanoma Therapeutics Market By Diagnosis, From 2019-2024(USD Billion)
  16. Europe Ultrasound Market By Region, From 2019-2024(USD Billion)
  17. Europe Blood Tests Market By Region, From 2019-2024(USD Billion)
  18. Europe Dermatoscopy Market By Region, From 2019-2024(USD Billion)
  19. Europe Sentinel lymph node biopsy Market By Region, From 2019-2024(USD Billion)
  20. Europe X-rays Market By Region, From 2019-2024(USD Billion)
  21. Europe CT Scan Market By Region, From 2019-2024(USD Billion)
  22. Europe Melanoma Therapeutics Market By Treatment, From 2019-2024(USD Billion)
  23. Europe early melanoma Market By Region, From 2019-2024(USD Billion)
  24. Europe advanced melanoma Market By Region, From 2019-2024(USD Billion)
  25. Europe Melanoma Therapeutics Market By Advanced Melanoma, From 2019-2024(USD Billion)
  26. Europe Biological therapy Market By Region, From 2019-2024(USD Billion)
  27. Europe Targeted therapy Market By Region, From 2019-2024(USD Billion)
  28. Europe Surgery Market By Region, From 2019-2024(USD Billion)
  29. Europe Chemotherapy Market By Region, From 2019-2024(USD Billion)
  30. Europe Radiotherapy Market By Region, From 2019-2024(USD Billion)
  31. Europe Immune therapy Market By Region, From 2019-2024(USD Billion)
  32. U.K Melanoma Therapeutics Market By Cancer stage , From 2019-2024(USD Billion)
  33. U.K Melanoma Therapeutics Market By Cancer type , From 2019-2024(USD Billion)
  34. U.K Melanoma Therapeutics Market By Diagnosis, From 2019-2024(USD Billion)
  35. U.K Melanoma Therapeutics Market By Treatment, From 2019-2024(USD Billion)
  36. U.K Melanoma Therapeutics Market By Advanced Melanoma, From 2019-2024(USD Billion)
  37. Spain Melanoma Therapeutics Market By Cancer stage , From 2019-2024(USD Billion)
  38. Spain Melanoma Therapeutics Market By Cancer type , From 2019-2024(USD Billion)
  39. Spain Melanoma Therapeutics Market By Diagnosis, From 2019-2024(USD Billion)
  40. Spain Melanoma Therapeutics Market By Treatment, From 2019-2024(USD Billion)
  41. Spain Melanoma Therapeutics Market By Advanced Melanoma, From 2019-2024(USD Billion)
  42. Germany Melanoma Therapeutics Market By Cancer stage , From 2019-2024(USD Billion)
  43. Germany Melanoma Therapeutics Market By Cancer type , From 2019-2024(USD Billion)
  44. Germany Melanoma Therapeutics Market By Diagnosis, From 2019-2024(USD Billion)
  45. Germany Melanoma Therapeutics Market By Treatment, From 2019-2024(USD Billion)
  46. Germany Melanoma Therapeutics Market By Advanced Melanoma, From 2019-2024(USD Billion)
  47. Italy Melanoma Therapeutics Market By Cancer stage , From 2019-2024(USD Billion)
  48. Italy Melanoma Therapeutics Market By Cancer type , From 2019-2024(USD Billion)
  49. Italy Melanoma Therapeutics Market By Diagnosis, From 2019-2024(USD Billion)
  50. Italy Melanoma Therapeutics Market By Treatment, From 2019-2024(USD Billion)
  51. Italy Melanoma Therapeutics Market By Advanced Melanoma, From 2019-2024(USD Billion)
  52. France Melanoma Therapeutics Market By Cancer stage , From 2019-2024(USD Billion)
  53. France Melanoma Therapeutics Market By Cancer type , From 2019-2024(USD Billion)
  54. France Melanoma Therapeutics Market By Diagnosis, From 2019-2024(USD Billion)
  55. France Melanoma Therapeutics Market By Treatment, From 2019-2024(USD Billion)
  56. France Melanoma Therapeutics Market By Advanced Melanoma, From 2019-2024(USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample